Genzyme CorporateResearchSearchGenzyme Websites
Patients and FamiliesHeath Care Professionals

Health Care Professionals
About the Disease
About Renagel
Access to Renagel
GRIP Grant Program
Events
Related Links

Events

Every year, there are numerous meetings, conferences, seminars and other events addressing chronic kidney disease. For more information, please visit the Renagel booth while attending these meetings.




Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. Patients should be informed to take Renagel with meals and to adhere to their prescribed diets. See Renagel Full Prescribing Information. For more information, please see Full Prescribing Information for Renagel or call Genzyme Medical Information at 1-800-847-0069.

Search

Learn more about the UPDATED Renagel Medicare Part D Assistance Program.

Contact Information
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email
Terms and Conditions of Use | Privacy Policy |  This site is intended for United States residents only.
© 2008 Genzyme Corporation. All rights reserved. Renagel and Genzyme are registered trademarks of Genzyme Corporation